Mechanistically, PLK1 inhibitors reversed the activation of STAT3, which was initially triggered by both EGFR-TKIs and MEK/ERK inhibitors, and suppressed the subsequent transcriptional upregulation of its downstream target genes in EGFR-mutant NSCLC cell lines. The gene discussed is MAP2K7; the disease is non-small cell lung carcinoma.